Ondansetron: Phase III started

RedHill began the double-blind, placebo-controlled, U.S. Phase III GUARD trial to evaluate once-daily oral RHB-102 in 320 patients with acute gastroenteritis. RedHill plans to submit an MAA in Europe ...